文献速递肺结节与肺癌呼吸道感染

COVID-19对英格兰肺癌发病率的影响:2019与2020年国家肺癌审计快速癌症登记数据集分析

The Impact of COVID-19 on Lung Cancer Incidence in England: Analysis of the National Lung Cancer Audit 2019 and 2020 Rapid Cancer Registration Datasets.
PubMed 文献 · Chest · 2023-01-12

本研究基于英格兰国家肺癌审计快速癌症登记数据集,回顾性分析2019和2020年肺癌发病率。2020年首次全国封锁期间肺癌发病率较2019年同期下降26%(调整IRR 0.74,95%CI 0.71-0.78),其中非小细胞肺癌下降23%,小细胞肺癌下降45%;此后发病率几乎恢复至基线但无过度补偿(调整IRR 0.96,95%CI 0.94-0.98)。

要点

  • 2020年首次封锁期间肺癌发病率较2019年同期下降26%。
  • 小细胞肺癌发病率下降45%,降幅大于非小细胞肺癌的23%。
  • 封锁后发病率恢复至基线附近,但全年未出现补偿性上升。

核心结论

  • 英格兰2020年首次全国封锁期间肺癌发病率显著下降26%,且当年后续未出现补偿性回升。

研究设计与样本

  • 回顾性观察性研究,使用2019和2020年国家肺癌审计快速癌症登记数据集计算肺癌发病率,以国家统计局年中人口估计为分母。
  • 采用泊松回归按与2020年全国封锁相关的时间点比较发病率。

主要发现

  • 首次全国封锁期间肺癌发病率较2019年同期下降26%(调整IRR 0.74,95%CI 0.71-0.78)。
  • 非小细胞肺癌发病率下降23%(调整IRR 0.77,95%CI 0.74-0.81)。
  • 小细胞肺癌发病率下降45%(调整IRR 0.55,95%CI 0.46-0.65)。
  • 此后发病率几乎恢复至基线,无过度补偿(调整IRR 0.96,95%CI 0.94-0.98)。

临床怎么用

  • 提示大流行及封锁期间肺癌诊断服务受到显著冲击,应关注延迟诊断对分期和预后的潜在影响。
  • 小细胞肺癌发病率降幅更大,提示侵袭性较强的亚型可能受影响更明显,需加强高危人群筛查与及时转诊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The COVID-19 pandemic has caused significant disruption to health-care services and delivery worldwide. The impact of the pandemic and associated national lockdowns on lung cancer incidence in England have yet to be assessed. RESEARCH QUESTION: What was the impact of the first year of the COVID-19 pandemic on the incidence and presentation of lung cancer in England? STUDY DESIGN AND METHODS: In this retrospective observational study, incidence rates for lung cancer were calculated from The National Lung Cancer Audit Rapid Cancer Registration Datasets for 2019 and 2020, using midyear population estimates from the Office of National Statistics as the denominators. Rates were compared using Poisson regression according to time points related to national lockdowns in 2020. RESULTS: Sixty-four thousand four hundred fifty-seven patients received a diagnosis of lung cancer across 2019 (n = 33,088) and 2020 (n = 31,369). During the first national lockdown, a 26% reduction in lung cancer incidence was observed compared with the equivalent calendar period of 2019 (adjusted incidence rate ratio [IRR], 0.74; 95% CI, 0.71-0.78). This included a 23% reduction in non-small cell lung cancer (adjusted IRR, 0.77; 95% CI, 0.74-0.81) and a 45% reduction in small cell lung cancer (adjusted IRR, 0.55; 95% CI, 0.46-0.65) incidence. Thereafter, incidence rates almost recovered to baseline, without overcompensation (adjusted IRR, 0.96; 95% CI, 0.94-0.98). INTERPRETATION: The incidence rates of lung cancer in England fell significantly by 26% during the first national lockdown in 2020 and did not compensate later in the year.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Gysling S, Morgan H, Ifesemen OS, et al. The Impact of COVID-19 on Lung Cancer Incidence in England: Analysis of the National Lung Cancer Audit 2019 and 2020 Rapid Cancer Registration Datasets. Chest. 2023. PMID: 36640995. doi:10.1016/j.chest.2023.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。